Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1051 | 1051 | 1114 | 1256 | 1607 | 2540 |
Fund Return | 5.07% | 5.07% | 11.44% | 7.9% | 9.96% | 9.77% |
Place in category | 140 | 140 | 119 | 18 | 49 | 52 |
% in Category | 69 | 69 | 53 | 11 | 32 | 45 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Total Stock Market Ins Pls | 656.16B | 10.01 | 9.65 | - | ||
Vanguard 500 Index Admiral | 505.18B | 10.54 | 11.44 | 12.92 | ||
Vanguard Total Stock Market Admiral | 373.3B | 10.00 | 9.63 | 12.27 | ||
Vanguard Total Intl Stock Index Inv | 195.27B | 4.34 | 1.83 | 4.38 | ||
Vanguard Institutional Idx Instl Pl | 168.84B | 10.55 | 11.47 | 12.95 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Health Care Adm | 39.97B | 5.08 | 7.96 | 9.83 | ||
Fidelity Select Health Care | 10.35B | 6.82 | 2.07 | 10.49 | ||
T. Rowe Price Health Sciences | 8.77B | 7.95 | 3.54 | 11.75 | ||
Fidelity Advisor Health Care A | 6.23B | 6.58 | 1.78 | 9.69 | ||
Fidelity Advisor Health Care C | 6.23B | 6.39 | 1.02 | 8.88 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 7.32 | 732.80 | +1.09% | |
UnitedHealth | US91324P1021 | 6.79 | 495.42 | +0.32% | |
AstraZeneca | GB0009895292 | 5.60 | 11,988.0 | -0.32% | |
Merck&Co | US58933Y1055 | 4.81 | 131.19 | +0.36% | |
Novartis | CH0012005267 | 4.67 | 89.50 | -0.56% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Strong Sell | Sell |
Technical Indicators | Strong Buy | Strong Sell | Sell |
Summary | Neutral | Strong Sell | Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review